Chalmette Dialysis Ctr is a medicare approved dialysis facility center in Chalmette, Louisiana and it has 16 dialysis stations. It is located in Saint Bernard county at 4020 Paris Rd, Chalmette, LA, 70043. You can reach out to the office of Chalmette Dialysis Ctr at (504) 277-8423. This dialysis clinic is run as an Independent entity i.e it is not owned by any chain organization. Chalmette Dialysis Ctr has the following ownership type - Profit. It was first certified by medicare in April, 1981. The medicare id for this facility is 192515 and it accepts patients under medicare ESRD program.
| Name | Chalmette Dialysis Ctr |
|---|---|
| Location | 4020 Paris Rd, Chalmette, Louisiana |
| No. of Dialysis Stations | 16 |
| Medicare ID | 192515 |
| Managed By | Independent |
| Ownership Type | Profit |
| Late Shifts | No |
| 4020 Paris Rd, Chalmette, Louisiana, 70043 | |
| (504) 277-8423 | |
News Archive
A group of scientists at B.C. Cancer Agency have found that lung cancers in smokers have different genetic mutations and look different than lung cancer in non-smokers. According to senior scientist at the BC Cancer Agency Research Centre Wan Lam, this finding is significant because it means that from now on, research, treatments and diagnostics should be tailored to the distinct genetic variations in the different lung cancers instead of expecting that a one-size fits all approach will work. He said, "At the current time, treatment does not distinguish between these different types. The subtypes are all grouped together. But with this work, we are beginning to tease out the subtypes." The study was presented Tuesday at a conference in Philadelphia of the American Association of Cancer Research.
According to results from a Phase III safety and immunogenicity study presented today, Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine, [13-valent, adsorbed]) was shown to be immunogenic and generally well tolerated in healthy young children who had received at least three prior doses of Prevenar (Pneumococcal Saccharide Conjugated Vaccine, Adsorbed). These data were presented today at the 7th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD) in Tel Aviv, Israel.
Sensient Technologies Corporation plans to expand its pharmaceutical coating capabilities at its Color Group headquarters site in St. Louis, Missouri, in order to serve growing demand for its products.
Reuters: To strengthen U.S. national vaccine strategy, the country "needs to establish a permanent group that advises the government on vaccine safety and spend more money to address safety concerns about vaccines," according to a report released Friday by the Institute of Medicine.
› Verified 8 days ago
| NPI Number | 1992733547 |
| Doing Business As | Chalmette Dialysis Center |
| Address | 4020 Paris Rd Chalmette, Louisiana, 70043 |
| Phone Number | (504) 780-1422 |
News Archive
A group of scientists at B.C. Cancer Agency have found that lung cancers in smokers have different genetic mutations and look different than lung cancer in non-smokers. According to senior scientist at the BC Cancer Agency Research Centre Wan Lam, this finding is significant because it means that from now on, research, treatments and diagnostics should be tailored to the distinct genetic variations in the different lung cancers instead of expecting that a one-size fits all approach will work. He said, "At the current time, treatment does not distinguish between these different types. The subtypes are all grouped together. But with this work, we are beginning to tease out the subtypes." The study was presented Tuesday at a conference in Philadelphia of the American Association of Cancer Research.
According to results from a Phase III safety and immunogenicity study presented today, Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine, [13-valent, adsorbed]) was shown to be immunogenic and generally well tolerated in healthy young children who had received at least three prior doses of Prevenar (Pneumococcal Saccharide Conjugated Vaccine, Adsorbed). These data were presented today at the 7th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD) in Tel Aviv, Israel.
Sensient Technologies Corporation plans to expand its pharmaceutical coating capabilities at its Color Group headquarters site in St. Louis, Missouri, in order to serve growing demand for its products.
Reuters: To strengthen U.S. national vaccine strategy, the country "needs to establish a permanent group that advises the government on vaccine safety and spend more money to address safety concerns about vaccines," according to a report released Friday by the Institute of Medicine.
› Verified 8 days ago
| Dialysis patients with Hemoglobin data | 20 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 5 |
News Archive
A group of scientists at B.C. Cancer Agency have found that lung cancers in smokers have different genetic mutations and look different than lung cancer in non-smokers. According to senior scientist at the BC Cancer Agency Research Centre Wan Lam, this finding is significant because it means that from now on, research, treatments and diagnostics should be tailored to the distinct genetic variations in the different lung cancers instead of expecting that a one-size fits all approach will work. He said, "At the current time, treatment does not distinguish between these different types. The subtypes are all grouped together. But with this work, we are beginning to tease out the subtypes." The study was presented Tuesday at a conference in Philadelphia of the American Association of Cancer Research.
According to results from a Phase III safety and immunogenicity study presented today, Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine, [13-valent, adsorbed]) was shown to be immunogenic and generally well tolerated in healthy young children who had received at least three prior doses of Prevenar (Pneumococcal Saccharide Conjugated Vaccine, Adsorbed). These data were presented today at the 7th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD) in Tel Aviv, Israel.
Sensient Technologies Corporation plans to expand its pharmaceutical coating capabilities at its Color Group headquarters site in St. Louis, Missouri, in order to serve growing demand for its products.
Reuters: To strengthen U.S. national vaccine strategy, the country "needs to establish a permanent group that advises the government on vaccine safety and spend more money to address safety concerns about vaccines," according to a report released Friday by the Institute of Medicine.
› Verified 8 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 34 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 262 |
| Percentage of adult patients getting regular hemodialysis at the center | 98 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
A group of scientists at B.C. Cancer Agency have found that lung cancers in smokers have different genetic mutations and look different than lung cancer in non-smokers. According to senior scientist at the BC Cancer Agency Research Centre Wan Lam, this finding is significant because it means that from now on, research, treatments and diagnostics should be tailored to the distinct genetic variations in the different lung cancers instead of expecting that a one-size fits all approach will work. He said, "At the current time, treatment does not distinguish between these different types. The subtypes are all grouped together. But with this work, we are beginning to tease out the subtypes." The study was presented Tuesday at a conference in Philadelphia of the American Association of Cancer Research.
According to results from a Phase III safety and immunogenicity study presented today, Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine, [13-valent, adsorbed]) was shown to be immunogenic and generally well tolerated in healthy young children who had received at least three prior doses of Prevenar (Pneumococcal Saccharide Conjugated Vaccine, Adsorbed). These data were presented today at the 7th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD) in Tel Aviv, Israel.
Sensient Technologies Corporation plans to expand its pharmaceutical coating capabilities at its Color Group headquarters site in St. Louis, Missouri, in order to serve growing demand for its products.
Reuters: To strengthen U.S. national vaccine strategy, the country "needs to establish a permanent group that advises the government on vaccine safety and spend more money to address safety concerns about vaccines," according to a report released Friday by the Institute of Medicine.
› Verified 8 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Chalmette Dialysis Ctr with elevated calcium levels.
| Patients with hypercalcemia | 34 |
| Hypercalcemia patient months | 262 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 2 |
| Patients with Serumphosphor | 37 |
| Patients with Serumphosphor less than 3.5 mg/dL | 5 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 21 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 21 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 32 |
| Patients with Serumphosphor greater than 7 mg/dL | 20 |
News Archive
A group of scientists at B.C. Cancer Agency have found that lung cancers in smokers have different genetic mutations and look different than lung cancer in non-smokers. According to senior scientist at the BC Cancer Agency Research Centre Wan Lam, this finding is significant because it means that from now on, research, treatments and diagnostics should be tailored to the distinct genetic variations in the different lung cancers instead of expecting that a one-size fits all approach will work. He said, "At the current time, treatment does not distinguish between these different types. The subtypes are all grouped together. But with this work, we are beginning to tease out the subtypes." The study was presented Tuesday at a conference in Philadelphia of the American Association of Cancer Research.
According to results from a Phase III safety and immunogenicity study presented today, Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine, [13-valent, adsorbed]) was shown to be immunogenic and generally well tolerated in healthy young children who had received at least three prior doses of Prevenar (Pneumococcal Saccharide Conjugated Vaccine, Adsorbed). These data were presented today at the 7th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD) in Tel Aviv, Israel.
Sensient Technologies Corporation plans to expand its pharmaceutical coating capabilities at its Color Group headquarters site in St. Louis, Missouri, in order to serve growing demand for its products.
Reuters: To strengthen U.S. national vaccine strategy, the country "needs to establish a permanent group that advises the government on vaccine safety and spend more money to address safety concerns about vaccines," according to a report released Friday by the Institute of Medicine.
› Verified 8 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 27 |
| Patient months included in arterial venous fistula and catheter summaries | 214 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 78 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 10 |
News Archive
A group of scientists at B.C. Cancer Agency have found that lung cancers in smokers have different genetic mutations and look different than lung cancer in non-smokers. According to senior scientist at the BC Cancer Agency Research Centre Wan Lam, this finding is significant because it means that from now on, research, treatments and diagnostics should be tailored to the distinct genetic variations in the different lung cancers instead of expecting that a one-size fits all approach will work. He said, "At the current time, treatment does not distinguish between these different types. The subtypes are all grouped together. But with this work, we are beginning to tease out the subtypes." The study was presented Tuesday at a conference in Philadelphia of the American Association of Cancer Research.
According to results from a Phase III safety and immunogenicity study presented today, Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine, [13-valent, adsorbed]) was shown to be immunogenic and generally well tolerated in healthy young children who had received at least three prior doses of Prevenar (Pneumococcal Saccharide Conjugated Vaccine, Adsorbed). These data were presented today at the 7th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD) in Tel Aviv, Israel.
Sensient Technologies Corporation plans to expand its pharmaceutical coating capabilities at its Color Group headquarters site in St. Louis, Missouri, in order to serve growing demand for its products.
Reuters: To strengthen U.S. national vaccine strategy, the country "needs to establish a permanent group that advises the government on vaccine safety and spend more money to address safety concerns about vaccines," according to a report released Friday by the Institute of Medicine.
› Verified 8 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 27 |
| Hospitalization Rate in facility | 201.7 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 414.7 |
| Hospitalization Rate: Lower Confidence Limit | 103.9 |
News Archive
A group of scientists at B.C. Cancer Agency have found that lung cancers in smokers have different genetic mutations and look different than lung cancer in non-smokers. According to senior scientist at the BC Cancer Agency Research Centre Wan Lam, this finding is significant because it means that from now on, research, treatments and diagnostics should be tailored to the distinct genetic variations in the different lung cancers instead of expecting that a one-size fits all approach will work. He said, "At the current time, treatment does not distinguish between these different types. The subtypes are all grouped together. But with this work, we are beginning to tease out the subtypes." The study was presented Tuesday at a conference in Philadelphia of the American Association of Cancer Research.
According to results from a Phase III safety and immunogenicity study presented today, Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine, [13-valent, adsorbed]) was shown to be immunogenic and generally well tolerated in healthy young children who had received at least three prior doses of Prevenar (Pneumococcal Saccharide Conjugated Vaccine, Adsorbed). These data were presented today at the 7th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD) in Tel Aviv, Israel.
Sensient Technologies Corporation plans to expand its pharmaceutical coating capabilities at its Color Group headquarters site in St. Louis, Missouri, in order to serve growing demand for its products.
Reuters: To strengthen U.S. national vaccine strategy, the country "needs to establish a permanent group that advises the government on vaccine safety and spend more money to address safety concerns about vaccines," according to a report released Friday by the Institute of Medicine.
› Verified 8 days ago
The rate of readmission show you whether patients who were being treated regularly at Chalmette Dialysis Ctr were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 26.2 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 39.2 |
| Readmission Rate: Lower Confidence Limit | 15.5 |
News Archive
A group of scientists at B.C. Cancer Agency have found that lung cancers in smokers have different genetic mutations and look different than lung cancer in non-smokers. According to senior scientist at the BC Cancer Agency Research Centre Wan Lam, this finding is significant because it means that from now on, research, treatments and diagnostics should be tailored to the distinct genetic variations in the different lung cancers instead of expecting that a one-size fits all approach will work. He said, "At the current time, treatment does not distinguish between these different types. The subtypes are all grouped together. But with this work, we are beginning to tease out the subtypes." The study was presented Tuesday at a conference in Philadelphia of the American Association of Cancer Research.
According to results from a Phase III safety and immunogenicity study presented today, Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine, [13-valent, adsorbed]) was shown to be immunogenic and generally well tolerated in healthy young children who had received at least three prior doses of Prevenar (Pneumococcal Saccharide Conjugated Vaccine, Adsorbed). These data were presented today at the 7th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD) in Tel Aviv, Israel.
Sensient Technologies Corporation plans to expand its pharmaceutical coating capabilities at its Color Group headquarters site in St. Louis, Missouri, in order to serve growing demand for its products.
Reuters: To strengthen U.S. national vaccine strategy, the country "needs to establish a permanent group that advises the government on vaccine safety and spend more money to address safety concerns about vaccines," according to a report released Friday by the Institute of Medicine.
› Verified 8 days ago